Lumos Diagnostics Holdings Limited (ASX:LDX)

Australia flag Australia · Delayed Price · Currency is AUD
0.295
0.00 (0.00%)
At close: Mar 6, 2026
1,129%
Market Cap 234.00M
Revenue (ttm) 18.31M
Net Income (ttm) -13.88M
Shares Out 793.21M
EPS (ttm) -0.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 6,061,319
Average Volume 2,999,511
Open 0.285
Previous Close 0.295
Day's Range 0.280 - 0.305
52-Week Range 0.019 - 0.330
Beta 0.61
RSI 57.37
Earnings Date Feb 24, 2026

About ASX:LDX

Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company’s products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platfor... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 2018
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol LDX
Full Company Profile

Financial Performance

In fiscal year 2025, ASX:LDX's revenue was $12.40 million, an increase of 11.40% compared to the previous year's $11.13 million. Losses were -$7.18 million, -16.40% less than in 2024.

Financial numbers in USD Financial Statements

News

There is no news available yet.